Emmons S L, Pollack S B
Nat Immun Cell Growth Regul. 1985;4(4):169-77.
NK-1.1 antiserum - (BALB/c X C3H)F1 anti-CE - and NK-2.1 antiserum - NZB anti-BALB/c - detect genetically distinct alloantigens on C57BL/6 natural killer (NK) cells. We have analyzed whether these two alloantigens are associated with functional subsets of NK cells. For this study, nylon wool nonadherent C57BL/6 spleen cells (SC) were treated with complement (C) and NK-1.1 or NK-2.1 antisera and then tested for NK activity against a panel of tumor targets in 6- and 19-hour 51Cr release assays. The NK activity against the prototype NK target YAC-1 was reduced equally by both antisera. Similar reductions by both antisera were also observed when SC were tested against another murine lymphoma target, L5178c127v, against the C57BL/6 melanoma B16, and against the human liver cell line Chang. In contrast, NK activity to the lymphoma FBL-3 and the human erythroleukemia K562 was significantly reduced in SC treated with NK-2.1 antiserum and C, whereas SC treated with NK-1.1 antiserum and C showed either less reduction or no reduction in activity against these two cell lines. With two other targets, E male G2 and RBL-5, neither serum produced significant depletion of activity, Analysis of SC indirectly labeled with either NK-1.1 or NK-2.1 antiserum and fluorescein-labeled goat anti-mouse Ig, however, did not detect significant differences between NK-1+ and NK-2+ cell populations.
NK-1.1抗血清 - （BALB/c×C3H）F1抗CE - 和NK-2.1抗血清 - NZB抗BALB/c - 可检测C57BL/6自然杀伤（NK）细胞上遗传上不同的同种异体抗原。我们分析了这两种同种异体抗原是否与NK细胞的功能亚群相关。在本研究中，用补体（C）以及NK-1.1或NK-2.1抗血清处理尼龙毛非黏附性C57BL/6脾细胞（SC），然后在6小时和19小时的51Cr释放试验中检测其对一组肿瘤靶标的NK活性。两种抗血清对原型NK靶标YAC-1的NK活性降低程度相同。当检测SC对另一种小鼠淋巴瘤靶标L5178c127v、对C57BL/6黑色素瘤B16以及对人肝癌细胞系Chang的NK活性时，也观察到两种抗血清的降低程度相似。相比之下，用NK-2.1抗血清和C处理的SC对淋巴瘤FBL-3和人红白血病K562的NK活性显著降低，而用NK-1.1抗血清和C处理的SC对这两种细胞系的活性降低较少或没有降低。对于另外两个靶标E male G2和RBL-5，两种血清均未导致活性的显著消耗。然而，用NK-1.1或NK-2.1抗血清以及荧光素标记的山羊抗小鼠Ig间接标记的SC分析未检测到NK-1 +和NK-2 +细胞群体之间的显著差异。
